CytoMed Therapeutics (GDTC) Enterprise Value (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Enterprise Value for 5 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 56.73% to -$1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.6 million through Dec 2025, up 56.73% year-over-year, with the annual reading at -$1.6 million for FY2025, 55.91% up from the prior year.
  • Enterprise Value hit -$1.6 million in Q4 2025 for CytoMed Therapeutics, up from -$3.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.1 million in Q4 2022 to a low of -$6.7 million in Q4 2023.
  • Historically, Enterprise Value has averaged -$3.0 million across 5 years, with a median of -$1.9 million in 2021.
  • Biggest five-year swings in Enterprise Value: plummeted 485.32% in 2023 and later soared 56.73% in 2025.
  • Year by year, Enterprise Value stood at -$1.9 million in 2021, then surged by 38.53% to -$1.1 million in 2022, then tumbled by 485.32% to -$6.7 million in 2023, then soared by 43.92% to -$3.7 million in 2024, then skyrocketed by 56.73% to -$1.6 million in 2025.
  • Business Quant data shows Enterprise Value for GDTC at -$1.6 million in Q4 2025, -$3.7 million in Q4 2024, and -$6.7 million in Q4 2023.